ERBB2 and glioblastoma: In the phase 1 trial by Ahmed et al., we saw prolonged survival in glioblastoma multiforme (GBM) patients utilizing autologous HER2 CMV bispecific CAR-T cells for progressive GBM. Out of five patients that responded, three patients were noted to have prolonged survival lasting more than 24 months and were still alive at the time of reporting results [26].